Multiple myeloma (MM) is tightly dependent on inflammatory bone marrow microenvironment. IL-17 producing CD4+ T cells (Th17) sustain MM cells growth and osteoclasts-dependent bone damage. In turn, Th17 differentiation relies on inflammatory stimuli. Here, we investigated the role of miR-21 in Th17-mediated MM tumor growth and bone disease. We found that early inhibition of miR-21 in naive T cells (miR-21i-T cells) impaired Th17 differentiation in vitro and abrogated Th17-mediated MM cell proliferation and osteoclasts activity. We validated these findings in NOD/SCID-g-NULL mice, intratibially injected with miR-21i-T cells and MM cells. A Pairwise RNAseq and proteome/phosphoproteome analysis in Th17 cells demonstrated that miR-21 inhibition led to upregulation of STAT-1/-5a-5b, STAT-3 impairment and redirection of Th17 to Th1/Th2 like activated/polarized cells. Our findings disclose the role of miR-21 in pathogenic Th17 activity and open the avenue to the design of miR-21-targeting strategies to counteract microenvironment dependence of MM growth and bone disease.

Rossi M., Altomare E., Botta C., Gallo Cantafio M.E., Sarvide S., Caracciolo D., et al. (2021). miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma. LEUKEMIA, 35(3), 823-834 [10.1038/s41375-020-0947-1].

miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma

Botta C.;
2021

Abstract

Multiple myeloma (MM) is tightly dependent on inflammatory bone marrow microenvironment. IL-17 producing CD4+ T cells (Th17) sustain MM cells growth and osteoclasts-dependent bone damage. In turn, Th17 differentiation relies on inflammatory stimuli. Here, we investigated the role of miR-21 in Th17-mediated MM tumor growth and bone disease. We found that early inhibition of miR-21 in naive T cells (miR-21i-T cells) impaired Th17 differentiation in vitro and abrogated Th17-mediated MM cell proliferation and osteoclasts activity. We validated these findings in NOD/SCID-g-NULL mice, intratibially injected with miR-21i-T cells and MM cells. A Pairwise RNAseq and proteome/phosphoproteome analysis in Th17 cells demonstrated that miR-21 inhibition led to upregulation of STAT-1/-5a-5b, STAT-3 impairment and redirection of Th17 to Th1/Th2 like activated/polarized cells. Our findings disclose the role of miR-21 in pathogenic Th17 activity and open the avenue to the design of miR-21-targeting strategies to counteract microenvironment dependence of MM growth and bone disease.
Rossi M., Altomare E., Botta C., Gallo Cantafio M.E., Sarvide S., Caracciolo D., et al. (2021). miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma. LEUKEMIA, 35(3), 823-834 [10.1038/s41375-020-0947-1].
File in questo prodotto:
File Dimensione Formato  
s41375-020-0947-1.pdf

non disponibili

Tipologia: Versione Editoriale
Dimensione 2.86 MB
Formato Adobe PDF
2.86 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/513411
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 15
social impact